eMultipleSclerosis Review

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176) Hosted on Acast. See acast.com/privacy for more information.

What's the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic's Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Too many individuals with MS are not receiving access to the most effective care. Why? What's behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

How burdensome is spasticity for patients with MS? What's the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies? These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

In her Expert Commentary, Dr. Melanie Ward from West Virginia University's Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Where's the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient's condition does not meet the accepted MS diagnostic criteria — that need to be investigated? Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University's Hotel Dieu de France Hospital in Beirut, Lebanon, and the Cleveland Clinic's Mellen Center for Multiple Sclerosis, explains strategies to reduce misdiagnosis of MS. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn't? What does the evidence say? Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleSclerosis Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions? Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

COVID-19 vaccination. For many people with multiple sclerosis, it's not a simple and straightforward process. The DMT they're currently taking to control disease progression and moderate their symptoms — particularly if it's a beta cell- depleting agent — may prevent the vaccine from working as it's supposed to. What do clinicians need to know, and how should they explain it to their patients? Dr. Joseph Sabatino from the University of California San Francisco presented the basics in his recent newsletter issue; now he brings that information into the clinic in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Shared decision-making — what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients' concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most important, how can it be developed in the clinic? Join us in this eMultipleSclerosis Review podcast, as we talk about the why and how of shared decision-making in MS with PA Lisa Fox from the Department of Neurology at Johns Hopkins Hospital in Baltimore. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What's known about the potential longer-term risks associated with highly effective therapies? That's the focus of our discussion with Dr. Yujie Wang from the University of Washington and Johns Hopkins University, and Dr. Anne Damian-Yacoub from Johns Hopkins University in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

A “comprehensive MS center” — what is it? Which clinicians comprise a “multidisciplinary MS care team?” How does comprehensive MS care work in practice? How does it benefit patients?That's the focus of this non-CME-accredited eMultipleSclerosis Review podcast, where we answer those questions and more, with our special guest, Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Multiple Sclerosis at the OhioHealth Multiple Sclerosis Center.  Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common is cognitive impairment in children with MS? How can it be successfully addressed? These are some of the important questions Drs. Zongqi Xia and Kavita Thakkar from the University of Pittsburgh Medical Center discuss in this clinically focused eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. That's the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients' health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important. In this eMultipleSclerosis Review Podcast, Dr. Bardia Nourbakhsh from the Johns Hopkins School of Medicine provides clinical insight into reducing the disease burden of these common symptoms. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Disease reactivation during and after pregnancy is a challenge facing many women with MS and their clinicians. How can relapses be prevented? What are the benefits of pregnancy planning? What are the risk factors for postpartum MS reactivation? How can they be modified? These are the questions Dr. Kristen Krysko from the University of California San Francisco addresses in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

In this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

The central vein sign. Optical coherence tomography. Serum neurofilament light chain. New research has identified these markers as valuable in discriminating MS from mimicking conditions, and in predicting future disability.In this Issue, Dr. Michael Kornberg and Dr. Elias Sotirchos from the Johns Hopkins University School of Medicine discuss how these advances can impact clinical decision-making to provide better patient care. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Benjamin M. Greenberg, MD, MHS covers the important topic of Incorporating MRI Results in Treatment Decision Making in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Ellen M. Mowry, MD, MCR covers the important topic of New Insights into Lifestyle Modification in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Arun Venkatesan, MD, PhD and Scott Douglas Newsome, DO cover the important topics of personalizing DMT regimens and the risk of medication non-adherence in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.